Aura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Aura Biosciences, Inc. ( AURA ) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 2:35 PM EDT Company Participants Natalie Holles - President, CEO & Director Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Natalie Holles President, CEO & Director This is my first fireside chat in this job. Sean Laaman Morgan Stanley, Research Division Oh, is it? Natalie Holles President, CEO & Director Yes. Sean Laaman Morgan Stanley, Research Division Oh, fantastic. All right. I guess we're all good. Natalie Holles President, CEO & Director Are we live? Sean Laaman Morgan Stanley, Research Division Yes. Good afternoon, everyone. I'm Sean Laaman, Head of U.S. Mid-Cap Biotech Equity Research at Morgan Stanley, and welcome to Morgan Stanley's Global Healthcare Conference. Before we commence, to make you aware of some important disclosures, please see the Morgan Stanley Research Disclosures website at www.morganstanley.com/researchdisclosures, and if you have any questions, please reach out to your Morgan Stanley research sales representative. For this session, we have the pleasure of welcoming from Aura Biosciences, their President and CEO, Natalie Holles. Welcome, and thank you for your time today. Natalie Holles President, CEO & Director Thanks very much, Sean. I'm happy to be here. Question-and-Answer Session Sean Laaman Morgan Stanley, Research Division Okay. Congratulations on the, I guess it's a relatively new role, and you've been in the seat for a few months now. And what excited you most about the opportunity to lead Aura at this stage? Natalie Holles President, CEO & Director Certainly. It's been 4 months since I joined the company, and I'd say what got me excited on my way in was that Aura represented a late-stage clinical opportunity that was as de-risked clinically and from a regulatory perspective as anything that I'd seen. The Phase II data for our investigational product, bel-sar in early choroidal melanoma, it's a